Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
Top Cited Papers
- 4 December 2008
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 359 (23), 2456-2467
- https://doi.org/10.1056/nejmoa0805450
Abstract
Approximately 50% of patients with heart failure have a left ventricular ejection fraction of at least 45%, but no therapies have been shown to improve the outcome of these patients. Therefore, we studied the effects of irbesartan in patients with this syndrome. We enrolled 4128 patients who were at least 60 years of age and had New York Heart Association class II, III, or IV heart failure and an ejection fraction of at least 45% and randomly assigned them to receive 300 mg of irbesartan or placebo per day. The primary composite outcome was death from any cause or hospitalization for a cardiovascular cause (heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke). Secondary outcomes included death from heart failure or hospitalization for heart failure, death from any cause and from cardiovascular causes, and quality of life. During a mean follow-up of 49.5 months, the primary outcome occurred in 742 patients in the irbesartan group and 763 in the placebo group. Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% confidence interval [CI], 0.86 to 1.05; P=0.35). Overall rates of death were 52.6 and 52.3 per 1000 patient-years, respectively (hazard ratio, 1.00; 95% CI, 0.88 to 1.14; P=0.98). Rates of hospitalization for cardiovascular causes that contributed to the primary outcome were 70.6 and 74.3 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% CI, 0.85 to 1.08; P=0.44). There were no significant differences in the other prespecified outcomes. Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction. (ClinicalTrials.gov number, NCT00095238.)Keywords
This publication has 36 references indexed in Scilit:
- Telmisartan to Prevent Recurrent Stroke and Cardiovascular EventsThe New England Journal of Medicine, 2008
- Usefulness of N-Terminal Pro–Brain Natriuretic Peptide and Brain Natriuretic Peptide to Predict Cardiovascular Outcomes in Patients With Heart Failure and Preserved Left Ventricular Ejection FractionThe American Journal of Cardiology, 2008
- Radial artery conduit for coronary revascularization: as good as an internal thoracic artery?Current Opinion in Cardiology, 2007
- Population-based detection of systolic and diastolic dysfunction with amino-terminal pro–B-type natriuretic peptideAmerican Heart Journal, 2006
- Mechanisms of Diastolic Dysfunction in Heart FailureTrends in Cardiovascular Medicine, 2006
- What Mechanisms Underlie Diastolic Dysfunction in Heart Failure?Circulation Research, 2004
- Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) StudyCirculation, 2003
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureThe New England Journal of Medicine, 2001
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureThe New England Journal of Medicine, 1999
- Validity of the minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placeboThe American Journal of Cardiology, 1993